BRAF Antikörper

Produktnummer ABIN1724658

Dieses Anti-BRAF-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von BRAF in ELISA und IHC. Geeignet für Human. Dieses Primary Antibody wurde in 4+ Publikationen zitiert.

Kurzübersicht für BRAF Antikörper (ABIN1724658)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRAF Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC)

Klon: 1H12F1

Produktdetails anti-BRAF Antikörper

Verwendungszweck: BRAF Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of BRAF expressed in E. Coli.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1/10000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-BRAF Antikörper (ABIN1724658)

Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: "Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma." in: Annals of surgery, Vol. 244, Issue 5, pp. 799-804, (2006) (PubMed).

Terai, Matsuda: "The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf." in: The EMBO journal, Vol. 25, Issue 15, pp. 3556-64, (2006) (PubMed).

Noda, Kato, Yoshikawa, Arai, Togashi, Nagai, Konishi, Miki: "Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers." in: Journal of experimental & clinical cancer research : CR, Vol. 25, Issue 2, pp. 235-42, (2006) (PubMed).

Fullen, Poynter, Lowe, Su, Elder, Nair, Johnson, Gruber: "BRAF and NRAS mutations in spitzoid melanocytic lesions." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 19, Issue 10, pp. 1324-32, (2006) (PubMed).

Details zu BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Andere Bezeichnung: BRAF

Hintergrund: BRAF(V-raf murine sarcoma viral oncogene homolog B1 ) is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439).B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK),it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers.The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi,primary cutaneous melanomas and colorectal cancers.

Gen-ID: 673

UniProt: P15056

Pathways: MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie